Glb1 knockout mouse model shares natural history with type II GM1 gangliosidosis patientsMOLECULAR GENETICS AND METABOLISMIF3.52023-02-014OAAI
AdipoQ-a simple, open-source software to quantify adipocyte morphology and function in tissues and in vitroMOLECULAR BIOLOGY OF THE CELLIF2.72022-10-0111OAAI
Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicityACTA NEUROPATHOLOGICA COMMUNICATIONSIF5.72020-08-0618OAAI
Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1DISEASE MODELS & MECHANISMSIF3.32020-03-1324OAAI
Targeting GLB1 in mice by CRISPR/Cas9 genome editing: Establishing a novel model for type II GM1 gangliosidosisMOLECULAR GENETICS AND METABOLISMIF3.52020-02-010PREAI
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease (vol 14, 40, 2019)MOLECULAR NEURODEGENERATIONIF17.52020-01-152OAAI
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's diseaseMOLECULAR NEURODEGENERATIONIF17.52019-11-08109OAAI
Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brainNEUROBIOLOGY OF AGINGIF3.52018-07-0167OAAI
AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 diseaseHUMAN MOLECULAR GENETICSIF3.22018-06-0561OAAI
N-Butyl-L-deoxynojirimycin (L-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82017-11-2232PREAI
Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral SclerosisSCIENTIFIC REPORTSIF3.92017-07-1235OAAI
Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthaseHUMAN MOLECULAR GENETICSIF3.22015-10-1975OAAI